U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07557355) titled 'A Study of SRSD384 in Overweight or Obese Participants' on April 22.
Brief Summary: This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Overweight , Obesity
Intervention:
DRUG: SRSD384 injection
Administered S.C. per the protocol
DRUG: Placebo
Administered S.C. per the protocol
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sirius Th...